Financial Performance - The company's revenue for Q1 2023 was CNY 230,412,076.04, representing a 12.03% increase compared to CNY 205,665,754.61 in the same period last year[6] - Net profit attributable to shareholders reached CNY 14,855,718.00, a significant increase of 634.03% from CNY 2,023,854.94 in the previous year[6] - The net profit after deducting non-recurring gains and losses was CNY 8,945,243.79, up 697.11% from CNY 1,122,203.66 year-on-year[6] - Basic and diluted earnings per share were both CNY 0.09, an increase of 800% compared to CNY 0.01 in the same period last year[6] - Total operating revenue for Q1 2023 was 16,631,467.48, a significant increase from 2,793,791.45 in Q1 2022, representing a growth of approximately 496%[26] - Net profit for Q1 2023 reached 14,855,718.00, compared to 2,023,854.94 in the same period last year, marking a year-over-year increase of about 634%[26] - Basic and diluted earnings per share for Q1 2023 were both 0.09, up from 0.01 in Q1 2022, indicating a substantial improvement in profitability[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,024,445,118.45, a 1.18% increase from CNY 2,989,114,303.25 at the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 3,024,445,118.45, up from CNY 2,989,114,303.25 at the beginning of the year, reflecting a growth of 1.2%[22] - The total current assets reached CNY 1,368,615,054.54, compared to CNY 1,351,475,288.90 at the start of the year, indicating an increase of 1.9%[20] - The total liabilities as of March 31, 2023, were CNY 1,468,156,374.06, slightly up from CNY 1,447,682,082.36 at the beginning of the year, showing an increase of 1.4%[22] - The total non-current assets were CNY 1,655,830,063.91, up from CNY 1,637,639,014.35, reflecting a growth of 1.1%[20] - Short-term borrowings rose to CNY 257,017,934.21 from CNY 220,084,829.04, an increase of 16.8%[21] - The company's retained earnings increased to CNY 391,076,854.19 from CNY 376,221,136.19, a growth of 3.9%[22] - The total equity attributable to the owners of the parent company was CNY 1,556,288,744.39, compared to CNY 1,541,432,220.89 at the beginning of the year, indicating an increase of 1.0%[22] Cash Flow - The company's cash flow from operating activities was negative at CNY -17,180,234.31, slightly worse than CNY -16,025,127.81 in the same period last year, reflecting a decrease of 7.21%[6] - Cash flow from operating activities showed a net outflow of -17,180,234.31, slightly worse than the -16,025,127.81 recorded in Q1 2022[29] - The net cash flow from investing activities improved by 76.49%, amounting to CNY -88,514,280.15 compared to CNY -376,449,232.15 in the previous year[14] - Cash flow from investing activities resulted in a net outflow of -88,514,280.15, compared to -376,449,232.15 in the previous year, indicating a reduction in cash burn[29] - The net cash flow from financing activities surged by 4,596.57% to CNY 64,595,118.87, primarily due to increased borrowings[14] - Cash flow from financing activities generated a net inflow of 64,595,118.87, a significant increase from 1,375,366.95 in Q1 2022, reflecting improved financing conditions[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,202, with the largest shareholder holding 49.86% of the shares[15] Government Subsidies - The company received government subsidies totaling CNY 3,980,605.72 during the reporting period, contributing to its financial performance[8] Operating Costs and Expenses - Total operating costs for Q1 2023 were 220,505,096.35, up from 201,486,255.25 in Q1 2022, indicating a rise of approximately 9.5%[25] - Research and development expenses for Q1 2023 were 9,286,444.32, slightly down from 9,754,406.16 in Q1 2022, showing a focus on cost management in R&D[25] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 395,545,161.51 from CNY 424,044,443.62, representing a decline of 6.1%[19] - The company reported a total cash and cash equivalents balance of 237,472,437.22 at the end of Q1 2023, down from 575,070,614.85 at the end of Q1 2022[30] - The company received cash inflows from investment activities totaling 352,273,935.15, a significant increase from 30,353,258.20 in the previous year, indicating strong investment recovery[29]

证券代码：300871 证券简称：回盛生物 公告编号：2023-034 武汉回盛生物科技股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 武汉回盛生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司 定于 2023 年 05 月 09 日（星期二）15:30-17:00 在"价值在线"（www.ir- online.cn）举办武汉回盛生物科技股份有限公司 2022 年度业绩说明会，与投 会议召开时间：2023 年 5 月 9 日（星期二）15:30-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2023 年 5 月 9 日前访问网址 https://eseb.cn/144ZHWhBtzG 或使用微信扫描下方小程序码进行会 前提问，公司将通过本次业 ...

证券代码：300871 证券简称：回盛生物 1 武汉回盛生物科技股份有限公司投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | --- | --- | |-------------------------|-------|-----------------------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：300871 证券简称：回盛生物 武汉回盛生物科技股份有限公司投资者关系活动记录表 编号：2021-003 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|-------|--------------------------------------------------------------|----------------------|------------------------------------------------------------|----------|---------| | 投资者关系 \n活动类别 | | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n现场参观 \n广发证券 | \n \n \n \n周舒玥 | □分析师会议 \n 业绩说明会 \n□路演活动 \n 其他 \n长江证券 | 电话会议 | 高辰星 | | | | 中信证券 | 彭家乐 | 长江证券 | | 顾熀乾 | | | | 中信证券 | 罗 寅 | 华宝基金 | | 陆 恒 | | | | 中信证券 ...

Company Overview - Wuhan Huisheng Biological Technology Co., Ltd. focuses on the research, production, and sales of veterinary drugs, primarily for pigs, while also expanding into other areas such as poultry, aquaculture, pets, and ruminants [2][3]. - The company ranks among the top ten in the domestic veterinary chemical preparations market according to the China Veterinary Drug Association's report [3]. Competitive Advantages - **Research and Development**: The company has established a strong R&D system, collaborating with Huazhong Agricultural University and has received 11 new veterinary drug certificates by the end of 2021, with more expected in 2022 [3][4]. - **Industry Chain Extension**: New raw material projects are set to be completed this year, enhancing production capacity for key raw materials, which will lower costs and improve competitiveness [3][4]. - **Smart Manufacturing**: The company has automated production lines that have passed the new GMP certification, ensuring high-quality production [3][4]. - **Product Quality and Market Share**: A robust quality control system has led to increased market share among major clients [3][4]. Financial Performance - In 2021, the company invested approximately 46.89 million yuan in R&D, a 65.20% increase from the previous year, with plans for continued investment [4][5]. - The sales revenue from the aquaculture sector grew by 169.62% in 2021, marking it as a new growth point for the company [5]. Regulatory Environment - The new GMP standards require all veterinary drug manufacturers to pass inspections by June 1, 2022, with over 900 companies already compliant [4][5]. - The "antibiotic ban" policy is expected to increase demand for preventive medications and alternatives to antibiotics, providing new opportunities for the company's products [5][6]. Future Outlook - The company plans to launch new veterinary drugs, including "Taidirol Injection," which is a new generation of antibiotics with a long-lasting effect [5][6]. - Upcoming raw material projects, including the production of 1,000 tons of Tylosin and 600 tons of Tiamulin, are expected to commence in mid-2022, enhancing production capacity [6]. Challenges - The decline in gross margin in 2021 was primarily due to rising raw material costs and the impact of the pig farming industry's losses [6]. - Short-term investments in projects may increase depreciation costs but are expected to enhance long-term competitiveness and product quality [6].

转债代码：123132 转债简称：回盛转债 证券代码：300871 证券简称：回盛生物 1 武汉回盛生物科技股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | 分析师会议 ...

Financial Performance - The company's revenue for Q3 2022 was ¥274,460,009.01, representing a 30.59% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥19,893,333.71, an increase of 8.11% year-on-year, but a significant decrease of 77.95% year-to-date[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,978,010.55, up 3.43% for the quarter, but down 83.51% year-to-date[5]. - The company's basic earnings per share for Q3 2022 was ¥0.12, a 9.09% increase from the previous quarter, but a decrease of 77.78% year-to-date[5]. - The net profit for Q3 2022 was CNY 26,405,977.46, a decrease from CNY 119,728,893.47 in the same period last year, representing a decline of approximately 78%[20]. - Operating profit for Q3 2022 was CNY 30,433,524.16, down from CNY 138,122,968.60 year-over-year, indicating a decrease of about 78%[20]. - The company reported a decrease in sales revenue from CNY 771,279,447.62 in the previous year to CNY 666,798,759.38 in Q3 2022, a decline of approximately 13.5%[22]. - The basic and diluted earnings per share for Q3 2022 were both CNY 0.16, down from CNY 0.72 in the same period last year, a decrease of about 77.8%[20]. - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[19]. - The company's total profit for Q3 2022 was CNY 28,460,408.21, significantly lower than CNY 137,767,113.63 in the same quarter of the previous year, indicating a decline of about 79%[20]. Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was ¥73,333,293.95, down 38.68% compared to the previous year[5]. - The net cash flow from operating activities for the first nine months of 2022 was ¥73,333,293.95, a decrease of 38.68% compared to ¥119,590,909.85 in the same period of 2021, primarily due to an increase in accounts receivable[9]. - The net cash flow from investing activities was -¥800,628,862.76, a significant decline of 1,488.89% from -¥50,389,141.10 in the previous year, mainly due to increased purchases of financial products[9]. - The net cash flow from financing activities decreased to -¥55,047,377.41, down 1,089.15% from ¥5,565,130.91, primarily due to increased cash repayments of loans[9]. - The net increase in cash and cash equivalents was -¥782,282,322.99, a decrease of 1,146.48% compared to an increase of ¥74,753,982.87 in the previous year, mainly due to net outflows from investing activities[9]. - Cash flow from operating activities for Q3 2022 was CNY 73,333,293.95, compared to CNY 119,590,909.85 in the previous year, reflecting a decline of approximately 39%[22]. - Total cash flow from investing activities was negative CNY 800,628,862.76 in Q3 2022, worsening from negative CNY 50,389,141.10 in the same period last year[22]. - Cash flow from financing activities resulted in a net outflow of CNY 55,047,377.41 in Q3 2022, compared to a net inflow of CNY 5,565,130.91 in the previous year[23]. - The total cash and cash equivalents at the end of Q3 2022 stood at CNY 183,858,359.05, down from CNY 360,261,233.85 at the end of Q3 2021[23]. - The company's total assets at the end of Q3 2022 were ¥2,770,809,269.95, a 1.06% increase from the end of the previous year[5]. - The company's total assets as of September 30, 2022, amounted to CNY 2,770,809,269.95, slightly up from CNY 2,741,662,030.01 at the beginning of the year[18]. - Cash and cash equivalents were CNY 323,047,579.17, down from CNY 1,068,233,710.99 at the beginning of the year, indicating a significant liquidity reduction[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,259, with no preferred shareholders having restored voting rights[11]. - Wuhan Tongsheng Investment Co., Ltd. held 49.86% of the shares, amounting to 82,800,000 shares, with 7,500,000 shares pledged[11]. - The company repurchased a total of 1,522,850 shares, representing 0.92% of the total share capital, with a total transaction amount of ¥30,947,790.28[13]. Expenses and Liabilities - Management expenses increased by 34.81% year-to-date, primarily due to higher salaries and depreciation[8]. - The company experienced a 306.86% increase in financial expenses year-to-date, attributed to the capitalization of convertible bond interest[8]. - Current liabilities totaled CNY 593,053,059.52, an increase of 17.83% from CNY 503,268,977.63 in the previous period[17]. - The total non-current liabilities were CNY 618,392,189.95, showing a slight decrease from CNY 619,539,266.83 in the previous period[17]. - The total equity attributable to shareholders decreased to CNY 1,559,364,020.48 from CNY 1,618,853,785.55, reflecting a decline of 3.6%[18]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[19]. - The company has not disclosed any new product or technology developments, market expansions, or mergers and acquisitions in the current report[12].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥397 million, a decrease of 25.89% compared to ¥535 million in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥6.51 million, down 93.57% from ¥101 million in the previous year[22]. - The net cash flow from operating activities decreased by 58.34% to approximately ¥25.81 million, compared to ¥61.97 million in the same period last year[23]. - The basic earnings per share for the first half of 2022 was ¥0.04, a decline of 93.44% from ¥0.61 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥1.38 million, a decrease of 98.55% from ¥94.95 million in the same period last year[23]. - The company achieved operating revenue of ¥397,018,762.74, a decrease of 25.89% compared to the previous year[44]. - The net profit attributable to shareholders was ¥6,512,643.75, down 93.57% year-on-year[44]. - The decline in revenue was primarily due to the continued downturn in the downstream breeding industry, which affected the scale of breeding and the usage of veterinary drugs[44]. - Operating profit for the first half of 2022 was CNY 10,365,515.08, down from CNY 118,198,274.68 in the first half of 2021[196]. - Net profit for the first half of 2022 was CNY 6,512,643.75, a significant decline from CNY 101,328,223.25 in the first half of 2021, representing a decrease of approximately 94%[197]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥2.68 billion, a decrease of 2.19% from ¥2.74 billion at the end of the previous year[23]. - The net assets attributable to shareholders decreased by 3.29% to approximately ¥1.57 billion, compared to ¥1.62 billion at the end of the previous year[23]. - Total liabilities amounted to 1,116.09 million, a slight decrease from 1,122.81 million at the end of the previous year[192]. - The company's asset-liability ratio at the end of the reporting period was 41.62%, an increase of 0.67% compared to the end of the previous year[184]. - Total assets as of June 30, 2022, amounted to CNY 2,375,493,122.08, slightly down from CNY 2,392,531,740.25 at the beginning of the year[195]. - Total liabilities increased to CNY 857,517,112.54 as of June 30, 2022, compared to CNY 827,779,576.09 at the start of the year[195]. Research and Development - The company has established a research institute in collaboration with Huazhong Agricultural University, focusing on innovative drug development and clinical solutions[39]. - Research and development expenses increased by 16.79% to CNY 17,680,760.33, reflecting the company's commitment to innovation[58]. - Research and development expenses for the first half of 2022 were CNY 17,680,760.33, an increase from CNY 15,138,572.29 in the same period of 2021[196]. Product Development and Market Strategy - The company has obtained 142 veterinary drug approval numbers as of June 2022, focusing on pig medications while expanding into poultry, aquaculture, and pet pharmaceuticals[32]. - Revenue from poultry products increased by 3.29% and from aquaculture products by 1.96%, indicating a diversification strategy to mitigate cyclical fluctuations in the pig farming industry[33]. - The company successfully launched the fourth-generation animal-specific antibiotic, Tylosin Injection, and improved the fermentation process of Tylvalosin, increasing efficacy by 4.5% and average yield by 6.7% compared to 2021[33]. - The company has launched 11 pet health products and 2 pet medications, expanding its product offerings in the pet care market[33]. - The company aims to enhance its customer coverage and penetration in the pig medicine sector while expanding into other areas such as poultry and aquaculture to mitigate risks from the pig cycle[92]. Financial Management and Investments - The company reported a significant increase in financial expenses by 173.44% to CNY 2,829,847.73, mainly due to the accrual of convertible bond interest[58]. - The total amount of funds raised by the company is RMB 154,001.15 million, with RMB 42,542.20 million invested during the reporting period[72]. - The company made a significant investment of CNY 10,000,000.00 in Hubei Animal Health Technology Development Co., Ltd., acquiring a 100% stake[68]. - The company has committed to various projects with a total investment of RMB 129,000 million, of which RMB 127,929.90 million has been invested as of the reporting period[80]. Corporate Governance and Compliance - The company has not reported any significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[123]. - The company has not engaged in any major related party transactions during the reporting period, ensuring transparency and compliance[126]. - The company has not experienced any non-operating fund occupation by major shareholders or related parties during the reporting period, reflecting financial integrity[118]. - The company has adhered to all relevant environmental regulations and is actively working towards sustainable development[114]. Shareholder Information - The major shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.86% of the shares, totaling 82,800,000 shares, which are subject to a 36-month lock-up period[163]. - The total number of shareholders at the end of the reporting period was not specified, but significant changes in shareholding were noted among major shareholders[163]. - The company’s shareholding structure showed a slight decrease in the proportion of restricted shares from 50.10% to 50.04%[149]. Future Outlook - The company’s future outlook includes maintaining its current credit rating and managing its restricted shares effectively[160]. - The company plans to strengthen project management to ensure timely production of fundraising projects and actively expand the market to increase product market share[99].

Financial Performance - The company's revenue for Q1 2022 was ¥205,665,754.61, a decrease of 34.40% compared to ¥313,499,906.84 in the same period last year[5] - Net profit attributable to shareholders was ¥2,023,854.94, down 96.81% from ¥63,457,333.99 year-on-year[5] - Basic earnings per share dropped to ¥0.01, a decline of 97.37% from ¥0.38 in the previous year[6] - Total operating revenue for Q1 2022 was CNY 205,665,754.61, a decrease of 34.4% compared to CNY 313,499,906.84 in Q1 2021[28] - Gross profit for Q1 2022 was CNY 4,179,499.36, significantly lower than CNY 73,631,806.44 in Q1 2021, indicating a decline of 94.3%[30] - Net profit for Q1 2022 was CNY 2,023,854.94, a decrease of 96.8% compared to CNY 63,457,333.99 in Q1 2021[30] - Basic earnings per share for Q1 2022 were CNY 0.01, down from CNY 0.38 in Q1 2021[31] Cash Flow - The net cash flow from operating activities was -¥16,025,127.81, an improvement of 20.12% compared to -¥20,061,570.80 in the same period last year[6] - Total cash inflow from operating activities was 223,182,661.77, down from 305,652,169.46 in the previous period, indicating a decrease of approximately 27%[34] - Cash outflow from operating activities totaled 239,207,789.58, compared to 325,713,740.26 in the previous period, reflecting a decrease of about 26.5%[34] - The net cash flow from investing activities was -¥376,449,232.15, a decline of 347.08% compared to ¥152,360,259.27 in the previous year[15] - Cash inflow from investing activities was 30,353,258.20, down from 411,485,219.59 in the previous period, representing a decrease of approximately 92.6%[35] - Cash outflow from investing activities increased to 406,802,490.35, compared to 259,124,960.32 in the previous period, marking an increase of about 56.9%[35] - Cash inflow from financing activities was 70,000,000.00, up from 20,000,000.00 in the previous period, indicating a growth of 250%[35] - The net cash flow from financing activities was 1,375,366.95, compared to -18,216,687.38 in the previous period, showing a turnaround[35] - The ending cash and cash equivalents balance was 575,070,614.85, compared to 399,596,815.86 in the previous period, reflecting an increase of approximately 44%[35] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,701,491,465.45, a decrease of 1.47% from ¥2,741,662,030.01 at the end of the previous year[6] - Total liabilities for Q1 2022 were CNY 1,135,079,667.38, compared to CNY 1,122,808,244.46 in Q1 2021, showing a slight increase of 1.1%[27] - Current assets decreased to CNY 1,431,758,454.96 from CNY 1,598,881,606.08, a decline of 10.5% year-over-year[26] - Non-current assets increased to CNY 1,269,733,010.49 from CNY 1,142,780,423.93, reflecting an increase of 11.1%[27] - The company’s total liabilities increased by 40.00% in short-term borrowings, amounting to ¥140,000,000.00, due to increased borrowing during the reporting period[12] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,594[17] - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.80% of shares, amounting to 82,800,000 shares, with 7,500,000 shares pledged[18] - The top ten shareholders include several investment firms, indicating a diverse ownership structure[19] - The company reported cash dividends of RMB 3.31 per 10 shares, totaling RMB 55,028,262.43 distributed to shareholders[22] Research and Development - Research and development expenses increased by 64.91% to ¥9,754,406.16, reflecting the company's commitment to enhancing R&D efforts[14] - The company reported a significant increase in research and development expenses, which rose to CNY 9,754,406.16 from CNY 5,914,988.69, marking a growth of 64.1%[29] Performance Goals - The company adjusted its performance assessment indicators for the 2021 restricted stock incentive plan, requiring a net profit growth rate of no less than 30% for 2021[20] - The company plans to achieve a revenue or net profit growth of no less than 65% for 2022, based on 2020 figures[20] Other Information - The company experienced a 1124.09% increase in non-operating expenses, totaling ¥2,010,149.96, primarily due to increased donations for university collaborations[14] - The company has initiated the repurchase and cancellation of 195,200 shares from the 2021 incentive plan[21] - As of March 31, 2022, cash and cash equivalents decreased to RMB 682,339,687.30 from RMB 1,068,233,710.99 at the beginning of the year, a decline of approximately 36.2%[24] - Accounts receivable increased to RMB 249,964,032.82 from RMB 231,856,552.45, reflecting a growth of about 7.8%[24] - Inventory decreased to RMB 201,968,517.77 from RMB 231,550,585.15, a reduction of approximately 12.7%[24] - The company’s first quarter report was not audited[36]

Financial Performance - The company's sales revenue from group farming customers reached RMB 609.30 million, an increase of 41.03% compared to the previous year[7]. - The company's operating revenue for 2021 was ¥996,216,817.61, representing a 28.14% increase from ¥777,458,548.09 in 2020[27]. - The net profit attributable to shareholders decreased by 11.52% to ¥132,865,534.22 in 2021, down from ¥150,156,108.11 in 2020[27]. - The company achieved a historic breakthrough in sales performance with a revenue of 996.22 million yuan, representing a year-on-year growth of 28.14%[58]. - The total revenue for 2021 was CNY 937,754,212.27, with a year-on-year increase of 31.67%[70]. - The revenue from veterinary chemical preparations was CNY 845,575,303.03, accounting for 84.88% of total revenue, with a growth of 34.64% compared to the previous year[70]. - The revenue from exports surged by 240.07% to CNY 12,865,408.39, indicating strong international demand[70]. - The revenue from South China region grew by 90.87% to CNY 211,245,158.45, highlighting market expansion efforts[70]. Cash Flow and Assets - The net cash flow from operating activities surged by 222.07% to ¥155,718,489.99, compared to ¥48,349,261.08 in the previous year[27]. - The company's cash and cash equivalents at the end of the period reached 966.14 million yuan, up 238.39% year-on-year, primarily due to funds raised from convertible bonds and operational accumulation[64]. - The company's total assets at the end of 2021 reached ¥2,741,662,030.01, a 56.47% increase from ¥1,752,225,832.51 at the end of 2020[27]. - The company's cash dividend distributed to shareholders is RMB 55,028,262.44, which accounts for 100% of the total profit distribution[172]. Research and Development - The company’s R&D expenses rose by 65.20% year-on-year to 46.89 million yuan, reflecting a strengthened focus on technological innovation[64]. - The company has established four major R&D platforms, including the Hubei Animal Health Engineering Technology Research Center, to accelerate new drug development and commercialization[119]. - The company has made significant progress in developing new veterinary drugs, with one product already on the market and another in the final stages of clinical trials[80]. - The company has established a research institute in collaboration with Huazhong Agricultural University, focusing on innovative drug development and clinical solutions[48]. Market Position and Strategy - The company has established stable partnerships with well-known domestic agricultural enterprises, enhancing its market presence and brand recognition[41]. - The company holds 143 veterinary drug approval numbers, focusing on a diverse range of products including antimicrobial and antiparasitic drugs for pigs, poultry, aquaculture, and pets[43]. - The marketing strategy combines direct sales to large-scale breeding groups and a dealer model for small and medium-sized farms, ensuring comprehensive market coverage[50]. - The company is focusing on vertical integration in the upstream raw material industry and horizontal expansion in various animal health sectors[118]. Corporate Governance - The company has a governance structure that complies with relevant laws and regulations, enhancing its operational transparency[129]. - The company has established a dedicated investor relations section on its official website, facilitating communication with investors[129]. - The company’s board consists of 5 members, including 2 independent directors, ensuring compliance with governance standards[126]. - The company has implemented a network voting platform for shareholders to express their opinions during meetings, promoting shareholder engagement[125]. Employee and Management - The total number of employees at the end of the reporting period is 828, with 376 in the parent company and 452 in major subsidiaries[164]. - The company has established a performance evaluation mechanism for senior management, ensuring that the stock incentive plan aligns with the performance and contributions of the incentive targets[178]. - The company emphasizes a performance-based salary system, including basic salaries, performance bonuses, and project incentives for research personnel[166]. - The company has a total of 8 doctoral graduates, 44 master's graduates, and 176 bachelor's degree holders among its employees[165]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, adhering to regulations and promoting energy conservation and emission reduction in its operations[193]. - The company actively engages in social responsibility initiatives, including donations to educational institutions and organizing volunteer activities[195]. - The company has implemented measures to prevent fund misappropriation and ensure proper use of large funds[179]. - The company has signed a cooperation agreement with Huazhong Agricultural University, committing 100 million yuan for research in the animal protection industry, focusing on major disease prevention and new veterinary drug development[192].